Evidence map›Paper›PMID 42778788›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Anatomical-molecular interaction in glioblastoma: subventricular zone involvement and MGMT-related survival benefit.

Flavio Donnini, Alessandro Bonzani, Pierpaolo Pastina, Giuseppe Battaglia, Armando Perrella, Giulio Bagnacci, Salvatore Chibbaro, Alfonso Cerase, Maria Antonietta Mazzei, Giuseppe Minniti and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Flavio DonniniUnit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. flavio.donnini@student.unisi.it.ORCID http://orcid.org/0009-0005-4084-3672
Alessandro BonzaniUnit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Pierpaolo PastinaUnit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giuseppe BattagliaUnit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Armando PerrellaUnit of Diagnostic Imaging, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giulio BagnacciUnit of Diagnostic Imaging, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Salvatore ChibbaroUnit of Neurosurgery, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Alfonso CeraseUnit of Neuroradiology, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Maria Antonietta MazzeiUnit of Diagnostic Imaging, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy.
Paolo TiniUnit of Radiation Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBoth MGMT promoter methylation and subventricular zone (SVZ) involvement influence glioblastoma prognosis. We investigated whether SVZ involvement modifies the prognostic impact of MGMT promoter methylation.

methodsWe retrospectively analysed 117 adults with IDH-wildtype glioblastoma (CNS WHO 2021) treated with chemoradiotherapy (Stupp protocol) between 2019 and 2024. MGMT methylation was assessed by pyrosequencing (cut-off ≥10%). SVZ involvement was defined as overlap between the gross tumour volume and a 5-mm expansion from the lateral ventricular walls, including temporal horns. Overall (OS) and progression-free survival (PFS) were analysed using multivariable Cox models with an MGMT × SVZ interaction term and two sensitivity analyses.

resultsSVZ involvement occurred in 45 patients (38%). Median PFS and OS were 11 and 15 months. Median OS was 32 months in MGMT-methylated/SVZ-negative vs 13 months in MGMT-methylated/SVZ-positive cases (pairwise log-rank p=0.001). On multivariable analysis, MGMT methylation remained protective (HR 0.50, p=0.008), whereas SVZ involvement lost independent significance (p=0.16). The MGMT × SVZ interaction was significant for OS (HR 2.62, 95% CI 1.12-5.40; p=0.020) but not PFS (p=0.42), persisting across sensitivity analyses. Recurrences were predominantly in-field (72.0-81.8%).

conclusionSVZ involvement attenuates the survival benefit conferred by MGMT methylation, supporting combined anatomical-molecular stratification. Given the cohort size and lack of PFS effect, these findings are hypothesis-generating and do not justify modifying radiotherapy target volumes based on SVZ involvement alone.

Indexed as

GlioblastomaMGMT promoter methylationPrognostic interactionRadiotherapySubventricular zoneSurvival analysis

Identifiers

PMID42778788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.